Drug intelligence / Profile preview

amoxicillin clavulanate

Development stage
Approved
Lead developer
GSK
Modality
Small Molecules
Administration
Oral, Intravenous
01

Overview

Amoxicillin clavulanate is a combination antibiotic consisting of amoxicillin, a penicillin-class antibiotic, and clavulanic acid (clavulanate), a beta-lactamase inhibitor. Amoxicillin works by inhibiting bacterial cell wall synthesis, leading to bacterial death. However, some bacteria produce beta-lactamase enzymes that can inactivate amoxicillin; clavulanic acid inhibits these enzymes, thereby extending the spectrum of activity of amoxicillin against beta-lactamase-producing organisms. This combination is used to treat various bacterial infections including those of the ear, lungs (such as pneumonia and bronchitis), sinuses, skin and soft tissue, urinary tract infections, animal bites, and others. It is available in oral and intravenous formulations[1][2][3][4][5]. The drug was first approved for use in the United States in 1984[5].

Brand names
AugmentinAugmentin ES-600Augmentin XRAmoclanAlti-Amoxi ClavApo-Amoxi ClavNovo-Clavamoxin 125Novo-Clavamoxin125Novo-Clavamoxin-125Novo-Clavamoxin 250Novo-Clavamoxin250Novo-Clavamoxin-250Ratio-Amoxi Clav 250
Other names
co-amoxiclavamox-clav
02

Targets

PBP (Penicillin-binding protein family)β-lactamase

Beyond the preview

Go deeper on amoxicillin clavulanate.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Full profile access

Follow clinical development from study design and recruitment through results.

  • Trial phase
  • Status
  • Readouts

Indications & development

Full profile access

Explore development by indication, patient population, and geography.

  • Indications
  • Development status
  • Countries

Licensing & deals

Full profile access

Trace asset ownership, licensing agreements, and commercial partnerships.

  • Partners
  • Deal terms
  • Milestones

Patents & exclusivity

Full profile access

Explore the patent landscape and regulatory exclusivity around an asset.

  • Patents
  • Expiration dates
  • Exclusivity

Competitive landscape

Full profile access

Compare development programs by target, modality, and indication.

  • Competing assets
  • Targets
  • Development stage

Research & analysis

Full profile access

Connect source evidence and development news to your research questions.

  • Publications
  • News
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on amoxicillin clavulanate.

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call